Morgan Stanley backs Celldex Therapeutics for growth with barzolvolimab's market-leading potential in chronic urticaria. Read ...

Dr Adam Friedman recounts how AAD 2025 highlighted advancements in chronic spontaneous urticaria management, with discussion ...

Chronic spontaneous urticaria is an idiopathic syndrome defined by recurring itch, hives, or angioedema (or a combination of these symptoms) for more than 6 weeks. Remibrutinib, an oral ...

Hanna Newnham, 27, from Brighton, first noticed symptoms of cold urticaria - hives that appear after cold temperature ...

A 27-year-old has been left unable to drink chilled beverages or exercise outdoors in winter after developing a rare cold ...

A 27-year-old woman developed a rare cold allergy after Covid-19 and had her first anaphylaxis attack after a McDonald’s ...

For patients with symptomatic chronic spontaneous urticaria after treatment with second-generation H 1-antihistamines, ...

Patients with chronic spontaneous urticaria that was not controlled with H1 antihistamines experienced improvements in itch ...

Remibrutinib significantly reduces itch and hives in patients with chronic spontaneous urticaria in two identical randomized ...

In this randomized controlled trial, among patients with chronic spontaneous urticaria who continue to have symptoms while on ...

Morgan Stanley initiated coverage of Celldex (CLDX) with an Overweight rating and $46 price target Celldex is developing antibodies for ...

HANNA Newnham developed a life-threatening allergy to the cold after catching Covid-19. Now, she can’t exercise outdoors in winter or even enjoy a cold drink. “Even if my throat closes, I’ll keep ...